PASADENA Prasinezumab 12 month data

Prof Simon Lewis describes the press release reporting the 12 month data of the PASADENA study evaluating prasinezumab, a novel monoclonal...

COVID-19

Prof Simon Lewis delivers an overview on the impact of the COVID-19, coronavirus pandemic in relation to diseases like Parkinson’s and...

The evidence for exercise in Parkinson’s – Interview with Bas Bloem

See Prof Simon Lewis interview Prof Bas Bloem  – discussing his latest trial, which highlights the benefits of exercise. No evidence...

What’s in the Pipeline for Parkinson’s?

Prof Simon Lewis describes what’s in the Pipeline for Parkinson’s.  Some treatments have already made it through clinical trials but may...

The Australian Parkinson’s Mission

Prof Simon Lewis is the National Trials Lead for the newly announced Australian Parkinson’s Mission.  Watch to see how this program...

Disease Modifying Approaches – new treatments for Parkinson’s Disease. Interview with Roger Barker

Prof Simon Lewis (www.profsimonlewis.com) interviews international authority Prof Roger Barker about where the new treatment approaches for Parkinson’s Disease might come...

Cell Based Therapies (‘Stem Cells’ for Parkinson’s) – Interview with Roger Barker

So I was delighted because I managed to track down Professor Roger Barker who is my hero, my mentor and someone who really leads...

Novel treatments for Alzheimer’s

Research is identifying the key factors that are driving Alzheimer’s and this is certainly offering more hope for developing effective treatments....

Modifiable Risk Factors for Dementia

Whilst the number of people with Dementia is rising worldwide this may not be the whole story. Research is identifying that...

Comparing Parkinson’s Disease and Lewy Body Dementia

Same same…but different. Both Parkinson’s and Lewy Body Dementia share similar pathologies when studied down the microscope and clinically they can...